:602-610. OBJECTIVE: Divergent findings among prior studies on correlates of risk for postictal psychosis (PIP) suggest the value of a controlled study involving a relatively large number of patients. METHODS: The study population consisted of a consecutive series of 59 patients with partial epilepsy and a history of PIP, and 94 control patients with partial epilepsy and no history of PIP evaluated as inpatients with video-electroencephalography.
The groups did not differ significantly regarding demographic features. Exact tests yielded a subset of variables and a tentative interpretation that were evaluated further utilizing principal components analysis and logistic regression. RESULTS: PIP was associated with extratemporal versus temporal ( p = 0.036) or undetermined ( p = 0.001) localization of seizure onset, bilateral interictal epileptiform activity ( p = 0.017), secondary generalization ( p = 0.049), and history of encephalitis ( p = 0.018). Interictal slow activity was more frequently absent in control patients ( p = 0.045). PIP was associated with family histories of psychiatric disorders ( p = 0.007) and epilepsy ( p = 0.042), which themselves were significantly intercorrelated (r 0.225; p = 0.006). Age of onset or duration of epilepsy and lateralized electroencephalographic or magnetic resonance imaging asymmetries did not differ significantly between control and PIP groups. The analysis indicated four underlying domains of risk for PIP: ambiguous/extratemporal localization, family neuropsychiatric history, abnormal interictal electroencephalographic activity, and encephalitis. Each unit increase on a simple additive scale composed of 9 dichotomous independent variables multiplied the odds ratio for PIP by 1.71 (95% confidence interval, 1.36-2.15; p < 0.0001).
INTERPRETATION: PIP in partial epilepsy is associated with relatively broadly and bilaterallydistributed epileptogenic networks, genetic determinants of psychiatric disorders and seizures, and encephalitis. COMMENTARY P redictors of postsurgical outcome typically include ictal and interictal data obtained from video-EEG monitoring studies (which provide location and number of interictal and ictal foci), neuroimaging data (which reveal the presence of structural lesions, hippocampal atrophy, and other structural features), as well as taking into consideration the type of epileptic seizures (generalized tonic-clonic seizures vs complex partial seizures) the patient experiences. While psychiatric history is not typically thought of as a predictor of postsurgical seizure outcome, a history of postictal psychotic (PIP) episodes may be one of the exceptions.
Postictal psychosis corresponds to approximately 25% of psychosis associated with epilepsy. The prevalence rates of PIP episodes have been estimated to range between 6 and 10 percent (1) . In patients with partial epilepsy who have undergone a video-EEG, the yearly incidence of postictal psychosis was reported to be 6.4% (2) . Several case series have identified the following clinical characteristics of PIP episodes: 1)
A symptom-free period, ranging from 12 to 120 hours, occurs between the time of the last seizure and the onset of the psychiatric symptoms. 2) Insomnia and/or agitation is one of the initial symptoms; it precedes the onset of psychotic symptoms by 8 to 24 hours. 3) Psychotic episodes of relatively short duration (i.e., hours-to-days, rarely weeks) appear and consist of affect-laden delusions, hallucinations, agitation, and thought disorder. 4) The onset of postictal psychosis follows a 10-year history of a pharmacoresistant seizure disorder. 5) With administration of a low-dose antipsychotic medication or occasionally benzodiazepines, a prompt symptom remission transpires. 6) Finally, secondarily generalized tonicclonic seizures occur, often in clusters and with bilateral interictal and ictal foci (2) (3) (4) (5) (6) (7) . Accordingly, a study that involved 18 consecutive patients with partial seizure disorders and postictal psychosis found that a history of PIP episodes was predictive of bilateral ictal foci with an 89% certainty compared with the 18 controls (7). In the study by Alper et al., patients with postictal psychosis were significantly more likely than controls to have extratemporal or poorly localized ictal foci, generalized tonic-clonic seizures, as well as a history of encephalitis. Not surprisingly, the epilepsy-related variables associated with postictal psychosis in this study and in those While it may be reasonable to assume from these data that a history of PIP episodes might exclude patients from an epilepsy surgery evaluation, there are compelling reasons to do the opposite. While PIP episodes are of short duration and respond to low doses of antipsychotic medication, the long-term prognosis for these patients may not be all that favorable, as postictal psychosis can evolve into interictal psychotic episodes. For example, in a study of 18 consecutive patients with partial epilepsy and PIP episodes, 7 (39%) individuals went on to develop interictal psychotic episodes. In contrast, only 1 of the 18 control patients with partial epilepsy and no history of PIP episodes developed interictal psychotic episodes (8) . Other authors have replicated these findings (9) . Thus, in recommending epilepsy surgery for patients with postictal psychosis consideration must be given not only to the desire to achieve seizure freedom but also to the need to prevent the development of an interictal psychotic episode. However, not all patients have bilateral or extratemporal ictal foci, thus some individuals with PIP episodes may be good surgical candidates. Even for patients with bilateral, independent ictal foci, palliative surgery can be considered, if the mesial temporal sclerosis is unilateral and the majority of seizures (>80% of all recorded typical seizures) originate from the atrophic hippocampal formation. In addition, the neuropsychological and intracarotid sodium amytal test data would need to suggest that the patient is at low risk of suffering significant postsurgical memory deficits. Patients that meet these criteria have up to 50% probability of achieving a seizure-free state. However, a cautionary note is in order: when patients with PIP episodes are being evaluated for epilepsy surgery, they must be advised that the procedure will put them at an increased risk of postsurgical manic and depressive episodes, which are likely to occur during the first 3 months after surgery (10) .
Finally, given the data presented here, several practical steps can be taken to evaluate patients with a history of postictal psychosis or suspected to be at risk for postsurgical PIP episodes. In order to identify or rule out the presence of bilateral independent ictal foci, a relatively large number of epileptic seizures (>5 seizures) need to be recorded during the video-EEG. Prophylactic treatment with low-dose atypical antipsychotic drugs (e.g., risperidone or quetiapine) may be necessary to minimize the risk of developing postictal psychosis following the occurrence of the large number of seizures, particularly if they are generalized tonic-clonic (2). Regardless, patients, who have bilateral ictal foci identified by video-EEG, must be closely observed for the development of PIP episodes, particularly if there is a family history of psychiatric disorders. Indeed, in the study by Alper and colleagues, having a psychiatric family history was found to be an independent risk factor for developing PIP episodes (OR: 2.6, 95% CI: 1. 21-5.65 ). Yet, since PIP episodes can appear several days after the last seizure, often occurring after the individual has been discharged, patients and their families must be instructed to identify the common initial symptoms, as previously delineated (e.g., insomnia, agitation). If these symptoms are identified, a low dose of an atypical antipsychotic drug can be administered to abort the full-blown psychotic episode.
In conclusion, a history of postictal psychosis (or the development of PIP episodes in the course of a video-EEG) should serve a red flag to the presence of bilateral independent ictal foci and/or diffuse brain damage-both of which have been associated with a poor postsurgical seizure outcome. Yet, this red flag should not be interpreted as a categorical reason to exclude these patients from consideration for an evaluation of epilepsy surgery.
by Andres M. Kanner 33% ; complex partial alone, 16%; simple partial alone, 22%; and combination, 29%). Cortical location and oligodendroglioma and oligoastrocytoma subtypes were significantly more likely to be associated with seizures compared with deeper midline locations and astrocytoma, respectively ( p = 0.017 and 0.001, respectively; multivariate analysis). Of the 269 patients with seizures, 132 (49%) had pharmacoresistant seizures before surgery. In these patients, seizures were more likely to be simple partial and to involve the temporal lobe, and the period from seizure onset to surgery was likely to have been longer ( p = 0.0005, 0.0089, and 0.006, respectively; multivariate analysis). For the cohort of patients that presented with seizures, 12-month outcome after surgery (Engel class) was as follows: seizure free (I), 67%; rare seizures (II), 17%; meaningful seizure improvement (III), 8%; and no improvement or worsening (IV), 9%. Poor seizure control was more common in patients with longer seizure history ( p < 0.001) and simple partial seizures ( p = 0.004). With respect to treatment-related variables, seizure control was far more likely to be achieved after gross-total resection than after subtotal resection/biopsy alone (odds ratio 16, 95% confidence interval 2.2-124, p = 0.0064). Seizure recurrence after initial postoperative seizure control was associated with tumor progression ( p = 0.001). CONCLUSIONS: The majority of patients with LGG present with seizures; in approximately half of these patients, the seizures are pharmacoresistant before surgery. Postoperatively, > 90% of these patients are seizure free or have meaningful improvement. A shorter history of seizures and gross-total resection appear to be associated with a favorable prognosis for seizure control.
COMMENTARY

S
eizures occur in about half of children and 35 to 40 percent of adults with supratentorial tumors (1). Known risk factors for seizures in patients with tumors include low-grade tumors (rather than high grade), cortical involvement, and either a perirolandic or temporal lobe location (2) . Seizures are usually the first symptom in patients with low-grade gliomas, especially oligodendrogliomas (1). Brain neoplasms account for 10 to 30 percent of adult epilepsy surgery candidates (3) . Nonneuronal tumors, such as gliomas, are thought to cause seizures in peritumoral cortex via one or more of the following mechanisms: 1) alteration of the number and organization of excitatory and inhibitory synapses; 2) changes in neurotransmitters, their receptors, and related enzymes; and 3) development of secondary hippocampal sclerosis, also known as dual pathology, for tumors located in or near the medial temporal lobe (3).
Seizures and their treatment play a major role in the quality of life among patients with low-grade tumors. Patients with epilepsy and tumors seem to be particularly prone to adverse effects from antiepileptic medications (especially rash) and are at risk for significant drug interactions, notably those involving steroids and chemotherapy (1) . Evidence from a controlled study indicates that cognitive dysfunction in patients with lowgrade glioma is ascribed primarily to the use of antiepileptic drugs, whereas declines in health-related quality of life are related more to incomplete seizure control (4).
In the current paper, Chang and colleagues provide extensive seizure-related information for a large cohort of patients (over 300) undergoing surgery for histologically proven lowgrade gliomas. Many of their findings confirmed prior studies: risk of seizures was greater with cortical involvement and an oligodendroglial component to the tumor; seizures were more likely to be refractory if there was temporal lobe involvement or a longer duration of epilepsy; and postoperative seizure control was better with complete lesion resection or with shorter duration of seizures preoperatively.
From the epileptologist's standpoint, it is noteworthy that half (137/269) of the patients with preoperative seizures were fully controlled medically and half of that subgroup (61/137) had experienced only one seizure preoperatively. Thus, those patients were undergoing tumor surgery, not epilepsy surgery. Eighty percent of this subgroup had achieved seizure freedom for at least 6 months at the 1-year postoperative follow-up. Among those patients who never had seizures prior to resection, 2/53 developed new-onset seizure(s) postoperatively. Of the 132 patients with refractory seizures prior to surgery, 54% Epilepsy Currents, Vol. 9, No. 4 ( July/August) 2009 pp. 98-100 Wiley Periodicals, Inc. C American Epilepsy Society were seizure free for at least 6 months at 1-year follow-up. Although gross total resection was clearly a positive predictor of seizure freedom postoperatively in all patients with seizures (almost 90% were seizure free), it is not clear what percent of refractory patients with complete resection became seizure free. Prior studies have addressed this question and also have found that complete resection improves seizure outcome. For example, Zaatreh et al. reviewed 68 patients with intractable temporal lobe tumoral epilepsy, almost all of whom had low-grade tumors (5). Seizure freedom was achieved in 43/60 patients with total resection (with tumor-free margins confirmed by intraoperative frozen sections) compared with only 1/8 without complete resection.
This study does not and was not intended to shed light on the role of electrocorticography or intracranial monitoring for patients with tumors and refractory seizures. Nonetheless, electrocorticography was used for 63 cases, not necessarily refractory cases. Seizure foci, although never specifically defined, were identified in 26 of those having electrocorticography. These foci were resected if considered safe to do so, but the authors do not state how often resection occurred. Of the 26 cases, 15 (58%) were seizure free at 6 months; the percent of patients who were seizure free and had the identified seizure focus resected was not provided. While prior studies have specifically evaluated the use of electrocorticography, the role of extending resections based on intraoperative electrocorticography or prolonged intracranial monitoring (with its own significant risks and morbidity) to capture seizure onsets remains unclear. There is certainly room for improvement in seizure freedom outcome given that lesionectomy, as applied in this study and several others with a variety of low-grade lesions, results in long-term seizure freedom for just over half of patients with refractory epilepsy prior to surgery. Only a large, multicenter randomized study would be able to address this issue meaningfully. Similarly, the current study does not speak to dual pathology. In fact, Chang and colleagues do not mention mesial temporal sclerosis or hippocampal resections. Prior studies have strongly suggested that resection of both the lesion and mesial temporal structures are required for long-term seizure freedom in these cases, though the risks and benefits must be weighed carefully in each case (3, 6) .
There are other valuable findings from this study. First, Karnofsky performance scores were inversely related to seizure control, which again, shows the importance of seizure control for quality of life. Second, seizure recurrence predicted tumor recurrence. Thus, in someone who has been seizure free for some time, a recurrent seizure should prompt a repeat of neuroimaging. As Yogi Berra might say, "If your patient has recurrence, you should worry about recurrence."
There are additional limitations to the current study. Only those patients with proven gliomas were included. Histologic confirmation often is unavailable when making surgical decisions in this patient population, and other types of tumors can appear very similar on imaging but have different pathophysiology. For example, dysembryoplastic neuroepithelial tumors, which often resemble low-grade gliomas on imaging, seem to be highly associated with neighboring cortical dysplasia, which may affect the surgical approach (3, 7) . In addition, the Chang et al. study only included patients who underwent resection for their tumor. There may be many other patients with lowgrade gliomas and seizures who never came to surgery and were thus excluded from the analysis. Accordingly, some of the conclusions should be interpreted with this caveat in mind: for instance, although resection following a short duration of seizures is associated with better seizure outcome in this and other studies of benign lesions that are ultimately resected (including cavernous malformations), it does not necessarily mean that surgery needs to be performed after the first seizure or when seizures are easily controlled. Some of these patients will never require surgery.
Therefore, patient preference continues to play an important role in the management of seizures associated with lowgrade lesions. For those individuals who have the "get it out of there" approach (especially for patients with lesions that have the potential for growth, transformation, or bleeding) or who want to have an increased chance of eliminating chronic antiepileptic medication (which is higher with complete resection than with no resection), early surgery is likely the best option for them. Yet, there are others who have the "no one is going in my head" attitude, do not mind long-term serial neuroimaging studies and accept taking chronic medication. For the latter group, early surgery makes less sense; thus, watching and waiting is probably the most reasonable approach. Once it is clear that seizures are difficult to control, rapid consideration of surgery is recommended for both types of patients, as it is for all patients with refractory seizures. ). In addition, the abbreviation mMCD is used to describe a mild malformation of cortical development in which ectopic neurons are found in layer 1 or white matter, with the absence of any dyslamination (1). The surgical treatment of patients with FCD has evolved over time. Since scalp EEG interictal and ictal events tend to be more widespread in FCD than in patients with temporal lobe epilepsy (4) and MRI scans are often normal or reveal only subtle abnormalities (5), clinicians were initially reluctant to consider patients for surgery since outcomes were presumed to be poor. More recently, it was shown that the interictal ECoG had a unique focal signature in human FCD 6) and that the MRI may be focally abnormal in approximately 50% of patients with type 1 FCD and approximately 90% with type 2 FCD (1). Moreover, FDG-PET regions of hypometabolism appear to colocalize with the FCD lesion in 70 to 98 percent of patients (1,7). As a result, more recent surgical series report rates of seizure-freedom ranging from 50 to 80 percent (5, 8) . However, there is still considerable debate regarding the goals of surgery and how to define the epileptogenic zone that must be removed to achieve the highest rate of seizures freedom.
The epileptogenic zone in FCD has been defined in several different ways for the purpose of surgical excision. Although there is not a comprehensive list, most series describe an imaging abnormality, either defined by MRI or FDG-PET hypometabolism. Likewise, electrographic abnormalities can be recorded acutely with surface ECoG or from chronically implanted electrodes (6) . Histologic margins of the FCD lesion can also be defined. A controversy arises from the fact that there is little agreement regarding which of these various modalities best defines the epileptogenic zone and what exactly needs to be removed during surgery to increase the likelihood of an Engel I outcome.
For example, in the study by Krsek et al. involving 149 patients, 49 had their epileptogenic zone defined with acute intraoperative ECoG, without implantation of electrodes, while 100 patients underwent implantation of electrodes. Completeness of resection was defined as complete removal of the MRI abnormality and of "significant" ECoG abnormalities. In the group that underwent implantation of electrodes, the ECoG was the most critical factor in determining the epileptogenic zone, including areas of ictal onset as well as rapid spread. Although completeness of resection had the most significant impact on outcome, curiously the use of chronically implanted electrodes and the presence of an abnormality on MRI scan did not.
In contrast, Salamon et al. report a subgroup of 45 patients in whom FDG-PET was coregistered to stereotactic MRI for navigation in the operating room. In this group, the extent of resection was based on the FDG-PET abnormality that concurred with the ECoG abnormality, but ECoG abnormalities were not chased beyond the FGD-PET defined borders. Only one patient underwent implantation of electrodes in this group and seizure-free rates were extremely high (82%).
The report by Salamon et al. implies that implanted electrodes and ictal onsets may not be necessary to define the epileptogenic zone in patients with FDG-PET abnormalities. However, other recent reports emphasize the importance of MRI and implanted electrodes. For instance, Kim et al. describe a large series of 166 patients with FCD in whom all had MRI, 151 had FDG-PET, and 143 had implanted electrodes (5). Complete resection, based on removal of the MRI abnormality and the ECoG abnormality, was the greatest predictor of seizurefree outcome. Concordance of FDG-PET was not associated with better outcome-neither was a focal ictal onset zone or a focal lesion on MRI. Seizure-free rates were not as high as in the pediatric series presented by Salamon et al., guided primarily by FDG-PET.
MRI alone is clearly not adequate in guiding surgical resections for FCD, since the histologic abnormality and electrographic abnormality often occur beyond this margin; in fact, the histological margin can also extend beyond the electrographic margin (7) . Likewise, the FDG-PET area of hypometabolism is more widespread than the MRI abnormality (1). It would be interesting to compare the extent of the histologic abnormality with the area of FDG-PET hypometabolism. If indeed the two correspond, the finding would validate the use of FDG-PET in guiding surgical resections.
Another possible explanation for the association between completeness of resection of the FDG-PET abnormality and outcome can be drawn from an analogy with mesial temporal lobe epilepsy. FDG-PET clearly shows regions of hypometabolism that extend well beyond the epileptogenic zone. After selective amygdalohippocampectomy, FDG-PET hypometabolism often returns to normal, further demonstrating that these areas of brain are not part of the epileptic focus (9) . Along a similar line, the hypometabolic FDG-PET areas identified in FCD may represent regions of early ictal spread surrounding the ictal onset zone. Thus, FDG-PET guided surgery may just increase the overall volume of resected tissue in a nonspecific manner. To address this issue, it would be useful to obtain postresection FDG-PET in FCD patients for whom the FDG-PET abnormality was not completely removed, to assess whether or not metabolism normalized. information on its pharmacokinetics in this population is limited. OBJECTIVE: The purpose of this study was to investigate the effects of age and sex on PHT pharmacokinetics using stable-labeled (SL) isotopes of PHT or fosphenytoin (FOS) administered IV or IM while patients remained on their oral maintenance regimen. METHODS: Subjects were patients 18 years or older with epilepsy, but otherwise healthy, on a maintenance regimen of PHT who were not taking interacting medications. Subjects were given a single injection of a 100 mg dose of SL-PHT or SL-FOS followed by their usual morning PHT dose less 100 mg. Serial blood samples were collected up to 196 hours after the SL dose. Plasma PHT and SL-PHT concentrations were measured by a gas chromatographic-mass spectrometric assay. PHT pharmacokinetics were characterized using a population-based, nonlinear, mixed-effects model. RESULTS: Sixty-three subjects completed the study, 45 of whom were 65 years or older. There was no difference between adult and elderly or men and women in PHT clearance, distribution volume, and elimination half-life. The mean elimination half-life was 40 hours. CONCLUSIONS: Healthy elderly adults appear to have the same phenytoin (PHT) pharmacokinetics as younger adults. Reduced PHT dosage requirements may be due to age-related changes in patients' sensitivity to the therapeutic and toxic effects of the drug. The prolonged elimination half-life suggests that most patients can take PHT once daily and the time to reach steady-state may extend to 2-3 weeks.
COMMENTARY
T he study by Ahn et al. demonstrates once again that facts clinicians all know, upon further reflection, simply may not be true, as demonstrated by carefully gathered scientific evidence. Clinicians all know that, in general, the half-life of phenytoin is about 22 hours and that the volume of distribution of phenytoin is about 0.75 L/kg (1,2). These assumptions guide clinical decisions, such as the frequency of recommended daily dosing of phenytoin and calculations of dosing changes to achieve targeted serum levels.
Investigations of the pharmacokinetics of phenytoin in the older literature are largely represented by acute rather than steady-state studies, which often use low doses that more likely are associated with a shorter half-life. In addition, there are few studies of patients in the oldest age category (i.e., older than 84 years), when drug metabolism may change.
More recent studies of phenytoin have focused on differences in patient population and individual drug metabolism, Epilepsy Currents, Vol. 9, No. 4 ( July/August) 2009 pp. 102-104 Wiley Periodicals, Inc. C American Epilepsy Society often during chronic drug use. Pharmacogenetic influences on drug metabolism are now widely appreciated, with polymorphisms in the gene for cytochrome P450 2C19 (CYP2C19) responsible for the most interindividual variability in the handling of phenytoin (3) . Specific populations demonstrate significant variations in pharmacokinetics. For example, patients with severe, acute traumatic brain injury have shown clinically significant subacute alterations in metabolism of phenytoin, with differences in Vmax (maximum rate of metabolism) of 400% occurring within the first 2 weeks of trauma (4). Significant, rapid posttraumatic increases in average free fractions of phenytoin, from 17% on day 1 to 24% on day 10, also have been documented (4) . Alterations during pregnancy are well known (5) .
The study of Ahn et al. draws from two groups of people on chronic phenytoin therapy: generally healthy people living in the community and relatively healthy elderly individuals from nursing homes. The study enrolled 18 younger people between 18 and 64 years of age and 63 older subjects: 45 between 65 and 75, 18 between 75 and 84, and 10 who were 85 years or older. On the day of the infusion, the study protocol allowed subjects to remain on their usual dosage of phenytoin but substituted 100 mg of their usual morning dose with radioactive-labeled phenytoin. The labeled drug was administered intravenously or intramuscularly, avoiding individual differences in gastrointestinal drug absorption. Free and unbound levels were measured over the next 192 hours. The total serum levels of all subjects remained stable, as levels of the single, labeled dose diminished over the succeeding 196 hours.
The significant findings of this study lie both in the refutation of some beliefs about using phenytoin in the elderly and in the conclusive confirmation of other data. For instance, the phenytoin clearance (and thus the half-life) did not appear to change significantly over the adult lifespan, although older studies had suggested that age-related pharmacokinetic changes required lower dosing in the elderly. In contrast, in the study by Ahn and colleagues, there was a dramatic reduction in phenytoin clearance in the subjects of all ages with higher initial serum concentrations of the drug. At a serum concentration of 5 g/dL, the average half-life was 23.3 hours, while at a concentration of 25 g/dL, the half-life climbed to 68.5 hours. This finding suggests that once daily dosing of phenytoin is reasonable and that the time period to achieve a new serum level after a dosing change may take 2 weeks or more. The study showed that the volume of distribution of phenytoin did not change over the lifespan, and that it is closer to 0.894 than to the 0.7 L/kg cited in standard texts. Likewise, the unbound fraction of the drug appeared to be stable with aging, contrary to popular wisdom, which predicts lower average serum albumen levels (and thus higher free fractions of phenytoin) in the elderly (6) .
The design of this study, however, may limit the applicability of its findings in daily clinical practice, as the crucial issue of bioavailability was sidestepped by the use of parenteral administration of the labeled drug. While the stability of phenytoin clearance and volume of distribution is convincingly demonstrated by the study, the question of possible changes in oral drug absorption with age is still unanswered. In addition, some subjects were drawn from a selected population of nursing home residents, and the relative proportion of these residents in each age group studied is not provided. The elderly subjects were screened to include only those deemed to be "relatively healthy," an undefined term for a group that includes at least some individuals unable to care for themselves in the community. Study patients were not on drugs "known to interact with phenytoin." As the authors admit, this restriction may limit the applicability of their findings to the typical elderly person with epilepsy, who may be on polypharmacy or suffer from age-related inefficiencies in renal or hepatic function.
How might the clinician respond to the new findings in this study? The pharmacokinetic data, at least from this relatively healthy population, strongly support the use of once daily dosing of phenytoin at any age, if desired. In addition, they suggest that checking the serum level of phenytoin sooner than 2 weeks after a dose change, in either older or younger adults, will underestimate the effect of the change. Finally, the results support the use of a higher volume of distribution when calculating the effects of dosing changes of phenytoin.
Perhaps, there is another lesson to be gleaned from the publication of this paper: what clinicians all know can be very difficult to alter. An earlier pharmacokinetic study of both young and elderly adults, using virtually the same study protocol, also found an unexpectedly long elimination half-life in adults of all ages (7). This finding was true not only for phenytoin (40-50 hours) but also for carbamazepine (21 hours, vs the usually cited 12-17 hours). Similar data are cited in an older, definitive text on antiepileptic drugs (i.e., a phenytoin half-life of over 69 hours at a serum concentration of 40 mcg/mL), yet most practitioners rely on what everyone knows (8) . Perhaps the paper by Ahn et al. will serve as a corrective voice. health, social, and vocational needs. This cross-sectional study examined behavioral/emotional, cognitive, and linguistic comorbidities as well as their correlates in children with CAE. METHODS: Sixty-nine CAE children aged 9.6 (SD = 2.49) years and 103 age-and gender-matched normal children had semistructured psychiatric interviews, as well as cognitive and linguistic testing. Parents provided demographic, seizure-related, and behavioral information on their children through a semi-structured psychiatric interview and the child behavior checklist (CBCL). RESULTS: Compared to the normal group, 25% of the CAE children had subtle cognitive deficits, 43% linguistic difficulties, 61% a psychiatric diagnosis, particularly attention deficit hyperactivity disorder (ADHD) and anxiety disorders, and 30% clinically relevant CBCL broad band scores. The most frequent CBCL narrow band factor scores in the clinical/borderline range were attention and somatic complaints, followed by social and thought problems. Duration of illness, seizure frequency, and antiepileptic drug (AED) treatment were related to the severity of the cognitive, linguistic, and psychiatric comorbidities. Only 23% of the CAE subjects had intervention for these problems. CONCLUSIONS: The high rate of impaired behavior, emotions, cognition, and language and low intervention rate should alert clinicians to the need for early identification and treatment of children with CAE, particularly those with longer duration of illness, uncontrolled seizures, and AED treatment.
T he study by Sadleir et al. found that absence semiology varied more with the circumstances of occurrence (e.g., clinical features, age) than specific syndrome type. Their results reflect an earlier video-EEG finding of semiology variability among patients with childhood absence epilepsy as well as variability in the same child (1) . Multiple components among the several systems involved in producing absence seizures with spike-waves likely bring about this pleomorphism. The following reviews some of the relevant components.
The mechanism underlying absence epilepsy with spikewaves involves abnormal oscillatory rhythms in thalamocortical Epilepsy Currents, Vol. 9, No. 4 ( July/August) 2009 pp. 104-107 Wiley Periodicals, Inc. C American Epilepsy Society circuits, including the nucleus reticularis thalami, thalamic relay neurons, and cortical pyramidal neurons. Perturbations at one or multiple sites within this circuit can evoke bisynchronous spike-waves (2). During wakefulness, photic stimulation, and hyperventilation may evoke absence seizures with spike-waves; sleep also elicits bisynchronous spike-waves.
Epileptic activity evoked by visual stimuli in humans appears to be initiated by synchronously activated magnocellular pathways from the occipital cortex, thus it is part of the dorsal stream of efferents stemming directly to the frontal cortex or through the brainstem reticular formation (3). In the baboon Papio papio, the only known species with naturally occurring light sensitive seizures similar to those in humans, the light-induced epileptic discharges arise in the frontal Rolandic region but require visual afferents for their precipitation. Subsequent discharge propagates to the brainstem reticular formation, at which point the clinical seizure occurs. Involvement of the thalamus in this process has been documented in the Papio papio (4) .
Hyperventilation was associated with more absence seizures with spike-waves than any other state in the Sadleir et al. study. Although the mechanisms by which hyperventilation activates spike-waves and absence seizures remain unresolved, the resulting alkalosis as well as the decreases in pO 2 and pCO 2 may play significant roles (5, 6) . Alkalosis promotes gap-junction opening, and gap-junctions have been shown to enhance seizure activity both in the cortex (7) and the reticular nucleus of the thalamus (8) . About one-third of seizures recorded in the study by Sadleir and colleagues occurred during drowsiness or sleep and correlated with the transition from the tonic mode of thalamic neuronal firing to an oscillatory mode, from which spike-wave burst firing can emerge (9, 10) . The distinct mechanisms of these precipitants of the thalamocortical spike-wave circuitry likely perturb its malfunction differently, thus affecting various semiologies associated with absence with spike-waves. However, there are other potential variables.
Systemic pentylenetetrazol evokes bisynchronous spikewave discharges prior to convulsive seizures. Experimental evidence suggests that the mediodorsal and midline thalamic nuclei are involved in the generation of the convulsive phase. Neuroimaging studies also have demonstrated thalamic involvement (10) . In convulsive seizures, cortical afferents likely arise from these thalamic nuclei as well as from thalamic relay nuclei. However, the mediodorsal nuclei do not form a functional unit: there are several subdivisions, each supplying a different part of the prefrontal cortex (11) . Thus, the basis for another potential semiological variable is added.
Microelectrode recordings of feline cortical layers (using systemic penicillin) disclosed correlations with each of several components of resultant spike-wave complexes: 1) surface negative spike: excitation in upper cortical layers, 2) positive trough: excitation in lower cortical layers, and 3) wave: lower cortical layer inhibition (12) . Corticofugal impulses from the motor cortex correlate with lower cortical layer excitation in a study of focal epilepsy (13) . Therefore, motor phenomena associated with absence epilepsy with spike-waves indicate involvement with its lesser-known trough complex and any variability connected with this spike-wave component.
The anterior-posterior expression of spike-waves also may influence its associated motor manifestations. Bilateral placement of acute epileptogenic foci on monkey anterior frontal cortex produced absence seizures with no motor components, while progressively more posterior placements were associated with increased motor features from myoclonus to tonic-clonic events (14) . Additionally, the range of spike-wave frequency (1.5-4 Hz) likely influences absence motor manifestations. Clinical and experimental data indicate an inverse relationship between spike-wave frequency and cortical excitability-thus, with associated absence motor manifestations (15, 16) .
Among descending tracts that originate in the brainstem, motor manifestations of generalized seizures principally involve the reticulospinal system. The cortical afferents to the reticulospinal tract arise chiefly from the Brodmann areas 4 and 6 of the motor cortex (17) . Data suggest that the motor components of seizure output of the reticulospinal tract are influenced by the level of arousal, strength of cortical afferents, and location of cortical involvement.
Brainstem stimulation studies indicate that myoclonic seizures arise principally from the mesencephalic reticular formation. Velasco and Velasco demonstrated that tonic and atonic attacks reflect caudal involvement (18) , corresponding to the motor excitation property of the pons and mesencephalon and to the motor inhibition property of the ventral medial medulla (19, 20) . GABA experimental injection into rat lateral dorsal tegmental nucleus of the mesencephalic reticular formation incites myoclonus (21) , confirming the localization findings of myoclonus in the Velasco and Velasco study (18) . Thus, ocular and facial phenomena, such as eyelid myoclonia, are likely mediated by interneurons in periaqueductal gray of the mesencephalic reticular formation (22) . A neuronal pool in the lower brainstem may integrate masticatory automatisms, while reticular formation stimulation may elicit stereotyped limb movements (17, 23) .
However, the anatomical complexity of the brainstem reticular system, which is a wickerwork of long dendrites and axons with multiple collaterals, produces a moderate overlap of excitatory and inhibitory areas (14) . As was similar in the other potential mechanism sites, a complex interplay among reticular formation areas likely contributes to the variable motor accompaniments that occur with absence epilepsy with spikewaves. Moreover, the strength of stimulus to the brainstem reticular formation also influences resulting motor features. One study found that mild reticular formation stimulation evoked myoclonic phenomena, moderate stimulation produced a tonic response with limb flexion, and a strong stimulus elicited tonic limb extension (24) . Nonetheless, in some patients, a relatively consistent sequence of automatisms during absence seizures with spike-waves has been found: ocular, oral, and non-oral automatisms, in that order (25) . This finding suggests possible seizure progression within at least one of the involved systems described here.
From the number and extent of systems involved in the production of absence epilepsy with spike-waves, the substantial proportion of afflicted children with cognitive, attention, and related deficits described in the Caplan et al. study is not surprising. In addition, antiepileptic drugs likely impair learning and school performance to various degrees (26) . Antiepileptic drugs may disrupt normal sleep architecture. For instance, valproate was shown to increased stage 1 sleep (27) . Finally, stigma afflicts all patients with epilepsy, leading to anxiety and depression (28) , which also may impair cognitive performance at school or at work.
Physiological and anatomical variables at each stage of absence-spike wave production, from precipitant to brainstem, likely contribute to the inconsistency in both inter-patient and intra-patient motor manifestations, as seen in the study of Sadleir et al. and others (1, 25) . Therefore, the current classification system of absence syndromes that contains only distinct categories appears insufficiently flexible to portray such varying phenomena. Instead, a codification system with multiple arms has been proposed; it takes advantage of the multifaceted programmable database systems presently in use (29) . The Caplan et al. findings underscore the need for practicing physicians to monitor social aspects of all young patients with a seizure disorder, even those that appear to be relatively benign.
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